Roman Butler Fullerton & Co. Purchases New Shares in Halozyme Therapeutics, Inc. $HALO

Roman Butler Fullerton & Co. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 3,989 shares of the biopharmaceutical company’s stock, valued at approximately $489,000.

Several other large investors have also modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter worth approximately $33,000. CoreCap Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 98.0% in the 3rd quarter. CoreCap Advisors LLC now owns 303 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 150 shares during the period. MidFirst Bank acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at $27,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $28,000. Finally, Quantbot Technologies LP purchased a new stake in Halozyme Therapeutics in the 2nd quarter valued at $30,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Matthew Posard sold 5,230 shares of Halozyme Therapeutics stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the transaction, the director directly owned 53,609 shares in the company, valued at $5,818,720.86. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the completion of the transaction, the director owned 40,418 shares in the company, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 over the last three months. 2.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

HALO has been the subject of a number of recent research reports. Stifel Nicolaus set a $130.00 price target on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Citizens Jmp lifted their price objective on shares of Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Zacks Research upgraded shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 13th. Weiss Ratings raised shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a report on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $99.55.

Halozyme Therapeutics Stock Up 1.2%

Halozyme Therapeutics stock opened at $130.03 on Thursday. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $130.24. The stock has a 50 day moving average of $112.74 and a two-hundred day moving average of $82.87. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The stock has a market capitalization of $14.76 billion, a price-to-earnings ratio of 38.82, a PEG ratio of 0.47 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company’s revenue was up 47.7% on a year-over-year basis. During the same period last year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 8.31 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.